The ONLY "truths" that are accepted and likely to move the

New Post Public Reply Private Reply Replies (1) Message Board
adirondackhi R&J #63922
632
The ONLY "truths" that are accepted and likely to move the pps are those that come in the form of SEC filings and any accompanying press releases.

PR's without SEC documentation like an 8-K, 10-K or 10-Q, even though they may be entirely true, are ALWAYS smeared and discredited by the manipulating thieves.

They'll slam them as "stock pumping" by the company, so most often they do very little to increase the value of the stock. It serves mainly to pop the volume with knee-jerk trading and help the flippers, which of course means dumping and shorting just as long term investors have stated.

PR's that come with inked deals and SEC filings are great, but what's needed to get the pps to continue ratcheting upward is PROOF of major revenue growth and an ever increasing distribution footprint, which will come with indisputable documentation in the 10-Q's and 8-K's.

Investors will come and go. As revenue increases at an exponential rate, investors who can't wait for the verification in the 2nd quarter 10-Q may have to go, but they're departure won't stop the path the company is on. IMHO investors who fold now are not likely to find a better near term growth prospect for a buy and hold position.

I hear a lot of talk about better prospects, but for most that's all "hind sight" investment wisdom. If they knew for certain where those better prospects were, they'd already be in them and/or attained major wealth from having done so.

I'm 100% convinced that investors who fold now will not stop the growth rate of this company, but will only succeed in robbing themselves of being in position at the very moment that most longs have hung in there for, and that's the moment of "critical mass" as I like to call it.

That's when the revenue growth explodes, and along with our new financing terms, fuels expansion without heavy dilution and the pps heads for blue skies.
2

Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links

RMHB Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading